Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Neoplasms 1

Interventions

pembrolizumab 109Paclitaxel 65Cyclophosphamide 65Cisplatin 60Carboplatin 56Gemcitabine 48Radiotherapy 45Nivolumab 44fludarabine 38Docetaxel 38Pemetrexed 33Dexamethasone 32Capecitabine 32Lenalidomide 26fludarabine phosphate 25Rituximab 25Radiation 25Ipilimumab 25Doxorubicin 25Irinotecan 24Bevacizumab 24Azacitidine 24Vorinostat 23Vincristine 22Cytarabine 22Temozolomide 20Etoposide 20Oxaliplatin 19Fluorouracil 19atezolizumab 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Has results × tumor necrosis factor-alpha, CNGRC fusion protein, human × Clear all
NCT00305084 2019-10-04

Study of NGR-hTNF in Combination With Doxorubicin in Solid Tumors

AGC Biologics S.p.A.

Phase 1 Completed
15 enrolled 20 charts
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡